On 16 April 2025, Shanghai-based CDMO, Chime Biologics, announced that it has entered a strategic cooperation agreement with Polpharma Biologics “to advance the end-to-end development and manufacture” of an undisclosed biosimilar product for the global market. Under the agreement, Chime will provide Polpharma with biosimilar development support, including drug investigation and supply capabilities.
Polpharma currently manufactures biosimilars of natalizumab and ranibizumab. Its Tyruko®, biosimilar to Biogen’s Tysabri® (natalizumab), is approved in Europe (September 2023) the US (August 2023) and Australia (April 2025), and is marketed and distributed by Sandoz under a global commercialisation agreement.